

FIRST TIME GENERIC APPROVAL

Brand Name	Tepadina®
Generic Name	thiotepa injection
Drug Manufacturer	MSN Laboratories Private Limited

New Drug Approval

Dosage form(s): 15 mg/vial, 100 mg/vial Single-Dose Vials Injection

Therapeutic equivalent code: AP

FDA Approval Date: March 4, 2020

Indications for Use

Thiotepa injection is indicated for:

- The treatment of adenocarcinoma of the breast or ovary; controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities; treating superficial papillary carcinoma of the urinary bladder.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.